Ronald Levy

Q: What Schools Are Affiliated With Ronald Levy

Ronald Levy is affiliated with the following schools: University of British Columbia, University of California, Los Angeles, Princeton University, University of Valencia, Stanford University, University of Iowa

Ronald Levy's AcademicInfluence.com Rankings

Ronald Levy

Physics

#2857

World Rank

#4146

Historical Rank

physics Degrees

Download Badge

Physics

Ronald Levy's Degrees

PhD Physics Stanford University
Masters Physics Stanford University
Bachelors Physics Stanford University

Why Is Ronald Levy Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ronald Levy's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling (2000) (9767)
Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma (2017) (3053)
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. (1998) (2847)
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells (1996) (1905)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. (2003) (1339)
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. (1997) (1245)
Two populations of Ia-like molecules on a human B cell line. (1980) (1066)
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. (2004) (927)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma (2010) (851)
Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. (1982) (847)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. (2010) (778)
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. (2000) (695)
IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. (1997) (645)
'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns (2000) (625)
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. (1994) (600)
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma (1997) (572)
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. (2002) (568)
Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. (1992) (553)
Dendritic cell vaccines for cancer immunotherapy. (1999) (510)
Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. (1997) (486)
A clinical trial of anti-idiotype therapy for B cell malignancy. (1985) (461)
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. (2010) (434)
TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins (1990) (386)
Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study. (1999) (383)
Studies of a human T lymphocyte antigen recognized by a monoclonal antibody. (1980) (355)
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. (1996) (355)
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK (2015) (344)
Detection of T and B cell antigens hybridoma monoclonal antibodies: a biotin-avidin-horseradish peroxidase method. (1980) (333)
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. (2013) (328)
Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma (1993) (321)
Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA (2016) (313)
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. (2002) (305)
Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. (1999) (300)
Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. (2001) (298)
Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. (1999) (294)
Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. (2012) (290)
Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation (2015) (286)
Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. (1999) (284)
Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma (1986) (281)
Clonal evolution of a follicular lymphoma: evidence for antigen selection. (1992) (279)
The monoclonality of human B-cell lymphomas (1977) (278)
Eradication of spontaneous malignancy by local immunotherapy (2018) (275)
Impaired lymphocyte function in untreated Hodgkin's disease. (1974) (268)
The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. (1975) (266)
Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. (1985) (261)
RESPONSE OF CUTANEOUS T CELL LYMPHOMA TO THERAPY WITH HYBRIDOMA MONOCLONAL ANTIBODY (1981) (257)
DNA immunization induces protective immunity against B–cell lymphoma (1996) (257)
Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. (1978) (253)
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. (2013) (250)
Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. (2003) (247)
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody (2016) (243)
Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes (2002) (241)
Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. (2001) (235)
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. (2018) (235)
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. (2015) (235)
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. (2013) (228)
In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. (1981) (226)
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. (2011) (213)
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. (2012) (211)
Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. (1992) (206)
Biclonal B-cell lymphoma. (1984) (205)
Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. (1989) (204)
The Inference of Antigen Selection on Ig Genes1 (2000) (198)
A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies. (1979) (198)
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. (2014) (194)
Antigen Presentation Profiling Reveals Recognition of Lymphoma Immunoglobulin Neoantigens (2017) (194)
Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma (1983) (192)
Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study (2008) (188)
Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. (2004) (188)
IDEC-C 2 B 8 ( Rituximab ) Anti-CD 20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin ’ s Lymphoma (1997) (186)
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. (2010) (185)
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. (2012) (184)
Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. (2002) (183)
Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection (1992) (182)
Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. (2000) (181)
Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines (1978) (181)
LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. (2008) (178)
Exogenous immunoglobulin and the macrophage origin of Reed-Sternberg cells in Hodgkin's disease. (1978) (175)
Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. (1998) (174)
Mouse x human heterohybridomas as fusion partners with human B cell tumors. (1986) (173)
Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. (1987) (170)
Intratumoral Immunization: A New Paradigm for Cancer Therapy (2014) (167)
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. (2009) (165)
Predicting HLA class II antigen presentation through integrated deep learning (2019) (163)
Targeting CD137 enhances the efficacy of cetuximab. (2014) (160)
A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma (2008) (159)
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma (1994) (158)
Variation in gene expression patterns in follicular lymphoma and the response to rituximab (2003) (158)
The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. (2007) (158)
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression (2010) (157)
Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. (1990) (155)
Immunologic phenotype in 30 patients with diffuse large-cell lymphoma. (1980) (151)
Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. (1994) (150)
BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. (2003) (150)
TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen. (1990) (150)
Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies (2003) (149)
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. (2006) (148)
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. (2013) (148)
Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. (2000) (145)
Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. (1986) (144)
Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. (2002) (141)
Somatic Mutation in Human B‐Cell Tumors (1987) (141)
The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy (2004) (140)
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer (2018) (138)
Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. (2000) (136)
Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma. (1995) (136)
Current clinical trials testing combinations of immunotherapy and radiation. (2015) (130)
A single monoclonal antibody identifies T-cell lineage of childhood lymphoid malignancies (1983) (129)
A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines. (1996) (129)
Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. (1983) (128)
Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. (1996) (128)
Tumor therapy with monoclonal antibodies. (1983) (128)
Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. (1985) (128)
Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell (1991) (127)
Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. (1994) (126)
Immunopathology of follicular lymphomas. A model of B-lymphocyte homing. (1978) (125)
Single cell origin of bigenotypic and biphenotypic B cell proliferations in human follicular lymphomas (1988) (123)
Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization. (1978) (122)
Spontaneous release of the Leu-2 (T8) molecule from human T cells (1983) (122)
Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. (1987) (121)
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. (2009) (121)
Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. (2004) (120)
Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself1 (2007) (120)
Kinetics of B Cell Receptor Signaling in Human B Cell Subsets Mapped by Phosphospecific Flow Cytometry1 (2006) (118)
Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. (2007) (118)
The immunologic and clinicopathologic heterogeneity of cutaneous lymphomas other than mycosis fungoides. (1983) (117)
Ig VH gene expression among human follicular lymphomas. (1991) (116)
Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. (1981) (116)
Linkage of Foreign Carrier Protein to a Self-Tumor Antigen Enhances the Immunogenicity of a Pulsed Dendritic Cell Vaccine1 (2000) (115)
Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma—A Feasibility Study (1999) (114)
BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. (2002) (114)
The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies. (1975) (113)
A unique human B lymphocyte antigen defined by a monoclonal antibody. (1984) (113)
T-lymphocyte subsets in follicular lymphomas compared with those in non-neoplastic lymph nodes and tonsils. (1982) (110)
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. (2007) (107)
Selective stimulation of nonhistone chromatin protein synthesis in lymphoid cells by phytohemagglutinin. (1973) (101)
Clinical relevance of immunologic phenotype in diffuse large cell lymphoma. (1984) (101)
A human X-linked antigen defined by a monoclonal antibody (1980) (99)
Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo. (2018) (98)
HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. (2003) (97)
Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones. (1990) (97)
In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. (2018) (96)
Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. (1988) (95)
Cytotoxic T lymphocytes specific for self tumor immunoglobulin express T cell receptor delta chain (1989) (95)
Determinants of the antitumor effect of radiolabeled monoclonal antibodies. (1990) (92)
Combination strategies to enhance antitumor ADCC. (2012) (91)
A study of lymphoproliferative diseases comparing immunofluorescence with immunohistochemistry. (1978) (89)
The lymphoid system. Its normal architecture and the potential for understanding the system through the study of lymphoproliferative diseases. (1978) (88)
The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients. (1984) (88)
Biological and clinical implications of lymphocyte hybridomas: tumor therapy with monoclonal antibodies. (1983) (86)
Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses. (1987) (86)
Mutational hot spots in Ig V region genes of human follicular lymphomas (1988) (86)
Self-antigen recognition by follicular lymphoma B-cell receptors. (2012) (86)
Imaging activated T cells predicts response to cancer vaccines (2018) (85)
DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. (1999) (85)
The human HLA-DR antigens are encoded by multiple beta-chain loci. (1982) (84)
Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5' noncoding regulatory region of the BCL-6 gene. (2000) (83)
Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T‐regulatory cells (2009) (82)
Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. (1991) (81)
Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. (1985) (81)
Enhanced detection of the t(14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresis. (1991) (80)
AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity (2004) (79)
Autoantibody activity of immunoglobulins isolated from B-cell follicular lymphomas. (1991) (78)
Dna fragmentation and cell death mediated by t cell antigen receptor/cd3 complex on a leukemia t cell line* (1989) (78)
Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas. (1984) (77)
Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints. (2019) (75)
Shared idiotypes expressed by human B-cell lymphomas. (1989) (75)
Cutaneous lymphoblastic lymphoma with pre-B markers. (1983) (74)
Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. (2015) (74)
Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. (2001) (72)
Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system. (2005) (72)
Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. (2014) (71)
Results of a Phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHL) (2008) (71)
Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig. (2003) (70)
mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice (2018) (70)
Therapy of lymphoma directed at idiotypes. (1990) (69)
Transformation of mycosis fungoides: T-cell receptor beta gene analysis demonstrates a common clonal origin for plaque-type mycosis fungoides and CD30+ large-cell lymphoma. (1993) (69)
Subtypes of cutaneous T-cell lymphoma defined by expression of leu-1 and Ia. (1982) (69)
Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. (2003) (68)
DETECTION OF B-CELL LYMPHOMA IN PERIPHERAL BLOOD BY DNA HYBRIDISATION (1985) (67)
A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. (2009) (67)
Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. (1996) (67)
Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. (1997) (67)
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials (2016) (67)
Vaccines for lymphomas: idiotype vaccines and beyond. (2009) (65)
The use of a monoclonal anti-idiotype antibody to study the biology of a human B cell lymphoma. (1981) (64)
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. (2017) (63)
A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. (2014) (62)
Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2. (1987) (62)
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma (2019) (61)
Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. (2011) (61)
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling (2017) (60)
''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. (2007) (60)
Local Delivery of Ox40l, Cd80, and Cd86 mRNA Kindles Global Anticancer Immunity. (2019) (59)
The optimal application of forward and ninety-degree light scatter in flow cytometry for the gating of mononuclear cells. (1985) (58)
Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. (1992) (57)
A unique antigen on mature B cells defined by a monoclonal antibody. (1986) (57)
Mutation analysis of the 5' noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma: evidence for recurrent mutations and intraclonal heterogeneity. (2000) (57)
Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells. (2015) (56)
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. (2007) (56)
Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. (2005) (56)
Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells (1992) (56)
Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1 (2016) (56)
Apoptosis Stimulating Protein of p53 (ASPP2) Expression Differs in Diffuse Large B-cell and Follicular Center Lymphoma: Correlation with Clinical Outcome (2002) (56)
Activation of an excluded immunoglobulin allele in a human B lymphoma cell line. (1989) (55)
Diversity of T-cell antigen receptor variable genes used by mycosis fungoides cells. (1992) (55)
Immunoglobulin secretion by mouse X human hybridomas: an approach for the production of anti-idiotype reagents useful in monitoring patients with B cell lymphoma. (1980) (55)
Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma. (1994) (53)
Prevalence of antigen receptor variants in human T cell lines and tumors. (1989) (53)
Antiidiotype antibody therapy of B-cell lymphoma. (1989) (53)
Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival. (2005) (51)
Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity (2013) (51)
Idiotype variant cell populations in patients with B cell lymphoma (1986) (50)
Intratumoral Immunotherapy for Early-stage Solid Tumors (2020) (50)
Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. (2003) (49)
HLA-DR epitope region definition by use of monoclonal antibody probes. (1980) (48)
CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. (2012) (48)
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? (2020) (48)
Clinical Trials of Idiotype‐Specific Vaccine in B‐Cell Lymphomas (1993) (48)
In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. (2002) (47)
Functional immunoglobulin light chain genes are replaced by ongoing rearrangements of germline V kappa genes to downstream J kappa segment in a murine B cell line (1989) (47)
Discordance between surface and cytoplasmic expression of the Leu-4 (T3) antigen in thymocytes and in blast cells from childhood T lymphoblastic malignancies. (1985) (47)
Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma (2014) (47)
Expression of Active Murine Granulocyte‐Macrophage Colony‐Stimulating Factor in an Escherichia coli Cell‐Free System (2004) (45)
A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. (2011) (45)
Immunoarchitectural Patterns in Follicular Lymphoma: Efficacy of HGAL and LMO2 in the Detection of the Interfollicular and Diffuse Components (2010) (45)
Active and passive immunotherapy for lymphoma: proving principles and improving results. (2011) (45)
Metabolizable 111in chelate conjugated anti-idiotype monoclonal antibody for radioimmunodetection of lymphoma in mice (1986) (45)
Interleukin 3 is a growth factor for human follicular B cell lymphoma (1992) (44)
Differences in "host infiltrates" among lymphoma patients treated with anti-idiotype antibodies: correlation with treatment response. (1985) (44)
TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response. (1999) (44)
A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity (2012) (42)
Synergistic antitumor effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma. (1986) (42)
TCR vaccines for active immunotherapy of T cell malignancies. (1997) (42)
Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab (2009) (41)
Epstein-Barr virus-positive follicular lymphoma (2017) (41)
Quantitation and estimation of lymphocyte subsets in tissue sections. Comparison with flow cytometry. (1987) (40)
Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma (2009) (39)
Protective immunity against murine candidiasis elicited by Candida albicans ribosomal fractions (1981) (39)
Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. (2000) (39)
Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. (2009) (38)
Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma (2009) (37)
Detection ofT and B Cell Antigens with Hybridoma Monoclonal Antibodies: A Biotin-Avidin-Horseradish Peroxidase I (1980) (37)
Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma. (2001) (37)
B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins. (2014) (36)
Antigen selection in human lymphomagenesis. (1992) (36)
The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. (2009) (36)
Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry. (2001) (35)
Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2. (1988) (35)
The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene (2003) (35)
Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. (2005) (34)
Enhancing immunotherapy of STING agonist for lymphoma in preclinical models. (2018) (33)
The history of the development of vaccines for the treatment of lymphoma. (2000) (33)
CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. (2010) (33)
Antiproliferative monoclonal antibodies: detection and initial characterization. (1985) (32)
Antibody-directed targeting of liposomes to human cell lines: role of binding and internalization on growth inhibition. (1987) (32)
Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL) (2008) (31)
Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28 (CD28) and CD81 (2012) (31)
B-cell lymphomas present immunoglobulin neoantigens. (2019) (31)
Pan-leukocyte monoclonal antibody L3B12. Characterization and application to research and diagnostic problems. (1984) (31)
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma (2020) (30)
Cancer vaccines: pessimism in check. (2004) (30)
Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants. (1988) (30)
Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin (2019) (30)
An epitope of the transferrin receptor is exposed on the cell surface of high-grade but not low-grade human lymphomas. (1989) (30)
Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor. (1989) (30)
Melanoma vaccines: Prim and proper presentation (1998) (30)
Specificity of an anti-aluminium monoclonal antibody toward free and protein-bound aluminium. (1998) (29)
Single Cell Analysis Can Define Distinct Evolution of Tumor Sites in Follicular Lymphoma. (2021) (29)
B-lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti-idiotypic antibody to induce extracellular acidification. (1995) (29)
A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL. (2015) (28)
Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody (2012) (28)
Human normal and leukemia cell surface antigens. Mouse monoclonal antibodies as probes. (1978) (28)
Characterization of the mouse liver cell line FL83B. (1973) (28)
CD81 as a tumor target. (2017) (27)
Retention of an idiotypic determinant in a human B-cell lymphoma undergoing immunoglobulin variable-region mutation. (1987) (27)
Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. (1997) (27)
Syngeneic antiidiotypic immune responses to a B cell lymphoma. Comparison between heavy chain hypervariable region peptides and intact Ig as immunogens (1985) (26)
Alternative V kappa gene rearrangements in a murine B cell lymphoma. An explantation for idiotypic heterogeneity (1988) (26)
Synthesis of nuclear-associated proteins by lymphocytes within minutes after contact with phytohemagglutinin. (1972) (26)
BCL-6 mRNA expression in higher grade transformation of follicle center lymphoma: correlation with somatic mutations in the 5′ regulatory region of the BCL-6 gene (2002) (25)
A submicroscopic interstitial deletion of chromosome 14 frequently occurs adjacent to the t(14;18) translocation breakpoint in human follicular lymphoma (1993) (25)
Three BTK-Specific Inhibitors, in Contrast to Ibrutinib, Do Not Antagonize Rituximab-Dependent NK-Cell Mediated Cytotoxicity (2014) (25)
Induction of autoantibody responses to GM-CSF by hyperimmunization with an Id-GM-CSF fusion protein. (1995) (25)
Cell-free production of Gaussia princeps luciferase--antibody fragment bioconjugates for ex vivo detection of tumor cells. (2009) (25)
A rapid microassay of cellular immunity in the guinea pig and mouse. (1972) (24)
A single monoclonal antibody identifies T-cell lineage of childhood lymphoid malignancies. (1983) (24)
Expression of the human germinal‐centre‐associated lymphoma protein in diffuse large B‐cell lymphomas in patients with rheumatoid arthritis (2008) (24)
Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action. (1988) (24)
Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees. (2009) (24)
Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking (2018) (24)
Autologous bone marrow transplantation in T-cell malignancies: A case report involving in vitro treatment of marrow with a pan-T-cell monoclonal antibody (1982) (24)
First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas (2020) (23)
Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin. (1990) (23)
Karnofsky Lecture: immunotherapy of lymphoma. (1999) (23)
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity. (2022) (23)
Characterization of antigenic determinants on human myeloid colony forming cells with monoclonal antibodies. (1981) (23)
T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154 (2001) (22)
Biosynthesis, glycosylation, and in vitro translation of the human T cell antigen Leu-4. (1983) (22)
Functional Immunoglobulin Light Chain Genes Are Replaced by Ongoing Rearrangements of Germline Vk Genes to Downstream Jk Segments in a Murine B Cell Line (1989) (22)
TCR Vaccines against a Murine T Cell Lymphoma: A Primary Role for Antibodies of the IgG2c Class in Tumor Protection1 (2004) (22)
Multiple HLA-DR antigens: detection with monoclonal antibodies and translation in vitro. (1982) (22)
Chimaeric T-cell receptors specific to a B-lymphoma idiotype: a model for tumour immunotherapy. (1995) (22)
Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells. (2012) (21)
The efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including the bone marrow. (2011) (21)
Recombinant adenovirus vaccine encoding a chimeric T-cell antigen receptor induces protective immunity against a T-cell lymphoma. (2000) (21)
Molecular outcome prediction in diffuse large-B-cell lymphoma. (2009) (20)
REACTIVITY OF MONOCLONAL ANTIBODIES AGAINST HUMAN LEUCOCYTE ANTIGENS WITH LYMPHOCYTES OF NON‐HUMAN PRIMATE ORIGIN (1981) (20)
The early stimulation of protein synthesis in sensitized guinea pig lymph node cells by antigen. (1972) (20)
C-C chemokine receptor 1 expression in human hematolymphoid neoplasia. (2010) (20)
Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy. (2020) (19)
A rapid assay of cell mediated immunity to soluble antigens based on the stimulation of protein synthesis. (1972) (19)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia (2016) (18)
CELLULAR IMMUNOABSORPTION USING MONOCLONAL ANTIBODIES: ELECTIVE REMOVAL OF T CELLS FROM PERIPHERAL BLOOD AND BONE MARROW (1984) (18)
Lymphoma Regression Induced by Monoclonal Anti-Idiotypic Antibodies Correlates With Their Ability to Induce Ig Signal Transduction and Is Not Prevented by Tumor Expression of High Levels of Bcl-2 Protein (1994) (18)
Production in vitro of murine antibody to a human histocompatibility alloantigen (1978) (18)
Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand. (2007) (18)
The in vitro antibody response to cell surface antigens. I. The xenogeneic response to human leukemia cells. (1977) (18)
Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy. (1991) (18)
Cellular immunity in experimental glomerulonephritis of rats. I. Delayed hypersensitivity and lymphocyte stimulation studies with renal tubular antigens. (1971) (18)
Correspondence 2: Cancer vaccines: pessimism in check (2004) (18)
A role for clonal antigens in cancer diagnosis and therapy. (1979) (18)
Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model. (1991) (17)
Escherichia coli-based production of a tumor idiotype antibody fragment--tetanus toxin fragment C fusion protein vaccine for B cell lymphoma. (2011) (17)
A roadmap for discovery and translation in lymphoma. (2015) (17)
CD81 is a novel immunotherapeutic target for B cell lymphoma (2019) (17)
Immunomodulating antibodies and drugs for the treatment of hematological malignancies (2011) (17)
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. (2019) (16)
Cancer vaccines and T cell therapy. (2013) (16)
Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms. (2007) (16)
Survival in Follicular Lymphoma: The Stanford Experience, 1960–2003. (2007) (16)
Definition of the high-risk acute lymphoblastic leukemia patient by immunological phenotyping with monoclonal antibodies. (1981) (15)
IMPAIRED IMMUNE HEALTH IN SURVIVORS OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): A LARGE POPULATION‐BASED STUDY (2019) (15)
How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. (2021) (15)
A Polymorphism in the BCL-6 Gene is Associated with Follicle Center Lymphoma (2001) (15)
T‐Cell Immunopeptidomes Reveal Cell Subtype Surface Markers Derived From Intracellular Proteins (2018) (14)
Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies (2016) (14)
An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory (2021) (14)
Massively Parallel Single Cell RNA-Seq of Primary Lymphomas Reveals Distinct Cellular Lineages and Diverse, Intratumoral Transcriptional States (2016) (14)
A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL). (2013) (14)
Idiotypic variation in a human B lymphoma cell line. (1990) (13)
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial (2020) (13)
Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant. (2009) (13)
Analysis of FAS (CD95) Gene Mutations in Higher-Grade Transformation of Follicle Center Lymphoma (2003) (13)
Biosynthesis and processing of a human T lymphocyte antigen. (1982) (13)
Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. (2011) (13)
Re: Akasaka, H., et al., Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays. Cancer Res., 60: 2335-2341, 2000. (2001) (12)
Comparison of combinations of interferons with tumor specific and nonspecific monoclonal antibodies as therapy for murine B- and T-cell lymphomas. (1988) (12)
Influence of avidity and idiotope recognition on the modulation of surface immunoglobulin on malignant human B cells by rat monoclonal anti-idiotype antibodies. (1986) (12)
Monoclonal immunoglobulin rescue from a patient with chronic lymphocytic leukemia and autoimmune hemolytic anemia. (1979) (12)
Two Immunoglobul in G Fragment C Receptor Polymorphisms Independent ly Predic t Response to Rituximab in Pat ients With Fol l icular Lymphoma (2003) (12)
Idiotype vaccination for lymphoma: moving towards optimisation (2009) (12)
SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial (2016) (12)
A PHASE I STUDY OF UTOMILUMAB (PF‐05082566), A 4‐1BB/CD137 AGONIST, IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH CD20+ NON‐HODGKIN'S LYMPHOMA (2017) (11)
Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis (2016) (11)
Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma (2015) (11)
Ibrutinib (PCI-32765) Antagonizes Rituximab-Dependent NK-Cell Mediated Cytotoxicity (2013) (11)
Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma. (2014) (11)
An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory (2021) (11)
Targeting the tetraspanin CD81 reduces cancer invasion and metastasis (2021) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
In vitro cortisone sensitivity of in vivo cortisone-resistant thymocytes. (1975) (11)
A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies. (2013) (11)
Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo (2014) (10)
Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma (2014) (10)
Role of Ia-positive cells in induction of secondary human immune responses to haptens in vitro. (1980) (10)
Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma (2016) (10)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma. (2010) (9)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma (2020) (9)
New insights into the mechanism of action of immune checkpoint antibodies (2014) (9)
90Y-ANTI-CD20 MONOCLONAL ANTIBODY THERAPY (IDEC-Y2B8) FOR RECURRENT B CELL LYMPHOMA (1994) (9)
The in vitro antibody response to cell surface antigens. II. Monoclonal antibodies to human leukemia cells. (1977) (9)
Experimental immunizations with Candida albicans ribosomal fractions: protection and immunological aspects. (1980) (9)
Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5′ noncoding regulatory region of the BCL-6 gene (2000) (9)
Determination of anti-idiotype antibodies by surface plasmon resonance. (1998) (9)
Mutation of the ATM Gene is Not Involved in the Pathogenesis of Either Follicle Center Lymphoma or its Transformation to Higher-grade Lymphoma (2002) (9)
Suppression of anti-mouse immunoglobulin antibodies in subhuman primates receiving murine monoclonal antibodies against T cell antigens. (1987) (9)
Intratumoral immunotherapy relies on B and T cell collaboration (2022) (9)
A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin’s Lymphoma. (2004) (9)
Abstract 2941: Local tumor irradiation combined with α-PDL-1 immune checkpoint inhibition results in local and systemic anti-tumor responses: Successful translation of a mouse model to a human case series (2014) (8)
Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin (1990) (8)
2172 Randomized controlled study of 131I-Anti-B1 versus unlabeled-Anti-B1 monoclonal antibody in patients with chemotherapy refractory low grade non-Hodgkin's lymphoma (1997) (8)
Idiotype as a tumor-specific marker in childhood B cell acute lymphoblastic leukemia. (1988) (8)
Anti-idiotypes in B-cell tumor therapy. (1987) (8)
Induction of protection against candidiasis in tumor-bearing mice by vaccination with Candida albicans ribosomes. (1987) (8)
Directional cloning of cDNA using a selectable SfiI cassette. (1990) (8)
Long-Term Follow-Up of Patients Treated in a Phase 2 Trial with MyVax® Personalized Immunotherapy (Recombinant Id-KLH with GM-CSF) after Chemotherapy as Initial Treatment for Follicular Non-Hodgkin’s Lymphoma (NHL). (2005) (8)
Intratumoral Injection of TLR4 Agonist (G100) Leads to Tumor Regression of A20 Lymphoma and Induces Abscopal Responses (2015) (8)
Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA (2016) (8)
Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions. (2009) (8)
Mouse-human hybridomas. The conversion of non-secreting human B cells into Ig secretors. (1978) (8)
Monoclonal Antibodies to Human Lymphocytes (1984) (8)
Proteins synthesized in lymphoid cells early after activation by phytohemagglutinin. (1973) (8)
Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909 (2008) (7)
Systemic candidiasis in mice immunized with Candida albicans ribosomes (1985) (7)
Will monoclonal antibodies find a place in our therapeutic armamentarium? (1987) (7)
TREATMENT OF B‐CELL LYMPHOMA WITH I‐131 LABELED MURINE MONOCLONAL ANTIBODIES.: P10 (1987) (7)
Tumor resistance induced by syngeneic bone marrow transplantation and enhanced by interleukin 2: a model for the graft versus leukemia reaction. (1992) (7)
IMMUNOBIOLOGY Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD 20 antibodies (2014) (7)
METABOLIZABLE IN‐111 CHELATE CONJUGATED ANTI‐IDIOTYPE MONOCLONAL ANTIBODY FOR RADIOIMMUNODETECTION OF LYMPHOMA IN MICE (1984) (7)
Genetic Polymorphism of the Inhibitory IgG Fc Receptor FcγRIIb Is Not Associated with Clinical Outcome of Rituximab Treated Follicular Lymphoma Patients. (2005) (7)
Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas. (2015) (7)
Rituximab Variants with Re-Engineered Fc with Higher Affinity to Activating Fcγ R Eliminate the Functional Difference between Fcγ R Genotypes. (2005) (7)
Early evaluation of mixed leukocyte interactions in mice and guinea pigs using measurements of protein synthesis. (1973) (7)
Homogeneous antibodies directed against human cell surface antigens: I. The mouse spleen fragment culture response to T and B cell lines derived from the same individual. (1977) (6)
Molecular rescue of tumour‐specific T cell receptor idiotype from T cell lymphomas (2004) (6)
High-Dose Radioimmunotherapy of B Cell Lymphomas1 (1989) (6)
Cell-mediated immunity following experimental vaccinations with Candida albicans ribosomes (1983) (6)
An epitope on the transferrin receptor preferentially exposed during tumor progression in human lymphoma is close to the ligand binding site. (1991) (6)
Mouse × Human Hybridomas (1980) (6)
An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma. (2013) (6)
Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation (2014) (6)
Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics. (2016) (6)
The Number of CD25+ Tumor-Infiltrating Cells May Predict Clinical Response to Rituximab in Follicular Lymphoma Patients. (2004) (6)
Tumor-Infiltrating T Cells Are Not Predictive of Clinical Outcome in Follicular Lymphoma. (2006) (6)
ALTERNATIVE V K GENE REARRANGEMENTS IN A MURINE B CELL LYMPHOMA An Explanation for Idiotypic Heterogeneity (1988) (6)
Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression. (2021) (6)
Detection of antibodies against Candida albicans ribosomes by the enzyme linked immunosorbent assay (1984) (5)
Induction of candidicidal activity in mice by immunization with Candida albicans ribosomes (1986) (5)
Erratum: Depleting tumor-specific Tregs at a single site eradicates disseminated tumors (Journal of Clinical Investigation (2013) 123:11 (4980) DOI:10.1172/JCI73340) (2013) (5)
Site to Site Comparison of Follicular Lymphoma Biopsies By Single Cell RNA Sequencing (2019) (5)
Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results. (2011) (5)
Preliminary Report on a Phase I/II Study of Intratumoral Injection of PF-3512676 (CpG 7909), a TLR9 Agonist, Combined with Radiation in Recurrent Low-Grade Lymphomas. (2006) (5)
Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer. (2022) (5)
Antibody formation in experimental immunizations with Candida albicans ribosomal fractions (1978) (5)
Spontaneous T cell antigen receptor variants of a human T leukemia cell line. (1988) (5)
CD81 costimulation skews CAR transduction toward naive T cells (2022) (4)
In vitro tests that predict tumor-associated idiotype levels in the serum of patients with B cell lymphomas and leukemias. (1987) (4)
Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. (2014) (4)
Immunoglobulin G Fc Polymorphism Is Correlated with Rituximab-Induced Neutropenia Following Autologous Hematopoietic Cell Transplantation. (2004) (4)
Utility Of Non-Invasive Monitoring Of Circulating Tumor DNA At Diagnosis, Interim Therapy, and Relapse Of DLBCL Using High-Throughput Sequencing Of Immunoglobulin Genes (2013) (4)
Intratumoral CpG, Local Radiation, and Oral Ibrutinib Combine to Produce Effective in Situ Vaccination in Patients with Low-Grade B-Cell Lymphoma (2020) (4)
A Polymorphism in the C1qA Component of Complement Correlates with Prolonged Complete Remission Following Rituximab Therapy of Follicular Lymphoma. (2005) (4)
Radiolabeled antibodies: another form of cytotoxic treatment. (1991) (4)
Immunologic phenotype in large-cell lymphoma. (1980) (4)
LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma in the Pre- and Post-Rituximab Treatment Eras. (2007) (4)
Cell Surface Antigens on Normal and Neoplastic Human Lymphoid Cells (1982) (4)
Deep B and T Cell Repertoire Sequencing to Evaluate Minimal Residual Disease and T Cell Responses in a Therapeutic Vaccine Trial for Mantle Cell Lymphoma (2012) (4)
Targeting CD137 to enhance the antitumor efficacy of cetuximab by stimulation of innate and adaptive immunity. (2013) (4)
Overcoming the limitations of chemotherapy in the treatment of B-cell non-Hodgkin's lymphomas--an approach using radiolabeled peptide ligands. (1993) (4)
Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts. (2009) (4)
Isolation of anti-idiotypic antibodies to T cells using an anti-framework determinant antibody. (1987) (4)
Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab. (2012) (4)
A brief personal history of cancer immunotherapy at Stanford: if these walls could talk… (2014) (3)
Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient Survival in Independent Cohorts, and Correlates with Transformation to Diffuse Large B-Cell Lymphoma. (2009) (3)
In Situ Vaccination with a TLR9 Agonist and Anti-OX40 Antibody Leads to Tumor Regression and Induces Abscopal Responses in Murine Lymphoma (2016) (3)
148 90Y-anti-CD20 monoclonal antibody therapy for recurrent B cell lymphoma (1995) (3)
CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR SELF TUMOR IMMUNOGLOBULIN EXPRESS T CELL RECEPTOR S CHAIN (2003) (3)
Development of a Novel Virus-like Particle (VLP) Vaccine for Personalized B-Cell Lymphoma and Chronic Lymphocytic Leukemia Therapy (2015) (3)
In Situ Vaccination with Cpg and Anti-OX40 Antibody: Preclinical Optimization for Clinical Translation (2018) (3)
NF-κB Signaling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome (2010) (3)
Anti-idiotype antibodies reveal the existence of somatic mutation in human B cell lymphoma. (1987) (3)
Charge-Altering Releasable Transporters Enable Specific Phenotypic Manipulation of Resting Primary Natural Killer Cells (2020) (3)
INHIBITION OF LYMPHOMA HYBRIDS BY HUMAN INTERFERON (1980) (3)
Targeting syk kinase for the treatment of B-cell lymphoma (2007) (3)
[Farnesyl transferase inhibitors (anti-Ras). A new class of anticancer agents]. (1995) (3)
Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop (2016) (3)
Somatic Mutations in the Ig VH Genes of Human B Cell Lymphoma (1987) (3)
Eradication of Systemic Lymphoma By Local Immunotherapy (2017) (3)
The immunobiology of B cell lymphoma: clonal heterogeneity as revealed by anti-idiotype antibodies and immunoglobulin gene probes. (1986) (2)
MONOCLONAL ANTI-IDIOTYPE ANTIBODY THERAPY OF B-CELL LYMPHOMA: LYMPHOMA REGRESSION CORRELATES WITH THE ABILITY OF THE ANTIBODY TO INDUCE IMMUNOGLOBULIN SIGNAL TRANSDUCTION IN VITRO AND IS NOT PREVENTED BY TUMOR EXPRESSION OF HIGH LEVELS OF BCL-2 PROTEIN (1993) (2)
Potentiated B-Cell Antigen Receptor Signaling In Mantle Cell Lymphoma Is Associated With Overexpression Of Surface CD79B and IgM (2013) (2)
Therapeutic Potential of Anti-CD137 Antibody in Lymphoma. (2009) (2)
Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation (2019) (2)
Abstract B128: Timing and sequence of CpG and anti-OX40 is critical for in situ vaccination (2019) (2)
Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis (2015) (2)
A Novel Method for Producing Custom-Made Idiotype Vaccines for Lymphoma Immunotherapy Using a Cell-Free Expression System. (2004) (2)
Targeting CD137 enhances the efficacy of cetuximab. (2019) (2)
Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL). (2015) (2)
Monoclonal Antibodies in the Treatment of Human Leukemias and Lymphomas: Applications of Flow Cytometry (1984) (2)
Abstract LB-138: Stimulation of natural killer cells with an anti-CD137 antibody enhances the efficacy trastuzumab, cetuximab, and rituximab in HER2-expressing breast cancer, EGFR+ head and neck cancer, and CD20+ lymphoma (2012) (2)
Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma (2017) (2)
Ibrutinib Enhances the Anti-Tumor Immune Response Induced By Intratumoral Injection of a TLR9 Ligand (2014) (2)
Immunoglobulin G Fc Receptor Polymorphisms and Clinical Course in Follicular Lymphoma Patients. (2004) (2)
IDEC-C2B8: INITIAL PHASE II RESULTS IN PATIENTS WITH B-CELL LYMPHOMA (1994) (2)
The immunobiology of B-cell lymphoma. Studies with anti-idiotype antibodies (1985) (2)
Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL. (2015) (2)
Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro. (2022) (2)
CCR 20th Anniversary Commentary: Radioactive Drones for B-cell Lymphoma (2015) (2)
Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960-2003 (2008) (2)
Mono clonal antibody characterization of human myeloid colony forming cells (1981) (2)
Syk Kinase Inhibition by R406 Inhibits BCR Mediated B Cell Proliferation and Interferes with BCR Signal Transduction in Primary Tumor Samples. (2007) (2)
Proceedings: Daunomycin and adriamycin antitumor cell antibody conjugates. (1975) (2)
in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses (2012) (1)
Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma (2016) (1)
Abstract PR5: Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes integrating tumor and microenvironment (2010) (1)
In Situ Vaccination with IL-12Fc and TLR Agonist - a Crucial Role for B Cells in Generating Anti-Tumor T Cell Immunity (2021) (1)
Prolonged disease‐free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma (2011) (1)
Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations (2016) (1)
1999 keystone symposium on B lymphocyte biology and disease: B cell malignancy II session. (1999) (1)
Immunotransplant Expands Vaccine-Induced Memory T Cell Responses In Patients With Mantle Cell Lymphoma (2013) (1)
In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study (2010) (1)
Antigen presentation profiling reveals T-cell recognition of lymphoma immunoglobulin neoantigens (2016) (1)
Lymphoma-Expressed VEGF-a, VEGFR-1, VEGFR-2, and Microvessel Density Are Not Predictive of Overall Survival in Follicular Lymphoma (2008) (1)
Identification of peptide ligands for the antigen binding receptor expressed on human B-cell lymphomas. (1998) (1)
PHASE I/II CLINICAL TRIAL OF AN ACTIVATED WHOLE TUMOR CELL VACCINE FOLLOWED BY TRANSFER OF IMMUNE T CELLS IN PATIENTS WITH MANTLE CELL LYMPHOMA (2017) (1)
Adoptive Cell Therapy for Lymphoma: Use of CpG-Loaded Tumor Cells to Generate Potent Anti-Tumor CD4 T Cell Immunity. (2009) (1)
Two Alpha Chains and Three Beta Chains of Human Ia Antigens (1983) (1)
CD137 stimulation of natural killer cells to enhance the antilymphoma activity of rituximab. (2010) (1)
B-Cell Receptors Of Follicular Lymphoma Patients Recognize Themselves (2013) (1)
First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+ B-cell malignancies previously treated with anti-CD20 therapy. (2015) (1)
Examining the Heterogeneity of Follicular Lymphoma By Multi-Parameter Flow Cyotmetry in Previously Untreated Patients (2016) (1)
Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and Non-Injected Tumor Sites in Patients with Low-Grade Lymphoma (2018) (1)
A Profile of 648 Signaling Network Events Identifies Cell Subsets with Diverse, Abnormal Responses to Lymphocyte Stimuli within Follicular Lymphoma Tumors. (2007) (1)
T cell antigen receptor vaccines for active immunotherapy of T cell malignancies (1998) (1)
Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results (2011) (1)
Single Cell Analysis of Serial Lymphoma Biopsies Reveals Dynamic Immune Modulation and Predictors of Response in Patients Undergoing in Situ Vaccination (2020) (1)
Signaling Diversity in Human Lymphoma B Cells and in Tumor Infiltrating T Cells Correlates with Follicular Lymphoma Patient Clinical Outcomes (2008) (1)
DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma (2016) (1)
Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade (2014) (1)
Noninvasive molecular subtyping and risk stratification of DLBCL. (2016) (1)
lymphoma using pulsed-field gel electrophoresis Enhanced detection of the t(14;18) translocation in malignant (2011) (1)
cells infiltrating follicular lymphoma tumors from peripheral T cells High PD-1 expression and suppressed cytokine signaling distinguish T (2013) (1)
Combination Immunotherapy of Advanced Lymphoma with Oncolytic Vaccinia Virus and Checkpoint Inhibitor Following Local Tumor Irradiation (2014) (1)
Vaccines in lymphoma. (2004) (1)
Increased Incidence of Autoimmune and Infectious Diseases Among a Large Group of Diffuse Large B-Cell Lymphoma (DLBCL) Survivors: A Population-Based Study (2017) (1)
Identification of Tigit on Intra-Tumor T Cells As a New Target for Immune Checkpoint Blockade in Follicular Lymphoma (2016) (1)
T Cell Modulation Combined with Intratumoral CpG Cures Lymphoma without the Need for Chemotherapy. (2008) (1)
The radiobiological effect of 131I-anti-idiotype monoclonal antibody therapy (∗MAB) in murine b cell lymphoma compared with continuous decaying low dose fate and acutely fractionated external beam irradiation — work sponsored by astro research fellowship 1988–1989 (1989) (1)
A brief personal history of cancer immunotherapy at Stanford: if these walls could talk… (2014) (1)
Generation of CD8 T Cell-Mediated Protective Immunity against Tumor Escapees (2008) (1)
FcγR IIIa polymorphism and anti-idiotype humoral immune response predict clinical outcome in follicular lymphoma patients receiving idiotypic vaccination. (2004) (1)
recurrent B-cell lymphoma anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with Phase I clinical trial using escalating single-dose infusion of chimeric (2011) (1)
Partial Structural Characterization of Human HLA-DR Subsets Using Monoclonal Antibodies (1983) (1)
Cell‐Free Technology for Rapid Production of Patient‐Specific Fusion Protein Vaccines (2008) (0)
Abstract P4-04-01: Combination of intratumoral CpG with systemic anti-OX40 and anti-CTLA4 mAbs eradicates established triple negative breast tumors in mice (2012) (0)
CD137 Identifies a Population of Regulatory T Cells That Inhibit Anti-Tumor Immune Responses In Adoptive Immunotherapy (2010) (0)
Therapeutic Vaccine for Lymphoma: Lessons Learned and Future Directions (2008) (0)
Abstract IA25: Local immunomodulation at a single site of tumor generates a therapeutic immune response that cures metastatic disease at distant sites, including the brain. (2013) (0)
Therapeutic antitumor immunity induced by combined intratumoral injection of dendritic cells (DCs) and systemic chemotherapy in murine lymphoma. (2004) (0)
PARP14 is a novel target in STAT6 mutant follicular lymphoma (2022) (0)
variant cells antitumor effect nor prevent the emergence of idiotype-negative the addition of a short course of chemotherapy does not interfere with Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the (2011) (0)
A PHASE I/II TRIAL OF IBRUTINIB, INTRATUMORAL CPG AND LOCAL RADIATION IN PATIENTS WITH LOW‐GRADE B‐CELL LYMPHOMA: INTERIM CLINICAL AND CORRELATIVE RESULTS (2019) (0)
Methods for T cell activation in vivo with antigen-incubated dendritic cells (1995) (0)
Response : Multiple BCL 6 translocation partners in individual cases of gastric lymphoma (2003) (0)
High-Throughput Sequencing Of T Cell Receptors Detects Signatures Of T Cell Repertoire That Predict MRD Status In Patients With Mantle Cell Lymphoma Undergoing Immunotransplantation (2013) (0)
Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies (2010) (0)
Activity of a Sting and a TLR9 Agonist As an “in Situ Therapeutic Vaccination” Against Lymphomas (2016) (0)
Mono clonal anti idiotype reagents for the study of a b cell tumor (1981) (0)
Self-Antigen Recognition by the B Cell Receptors of Follicular Lymphoma (2010) (0)
OR.10. Using Immune Response Data from a Lymphoma Vaccine Clinical Trial to Define Novel Endpoints for an Immunotransplant Trial (2009) (0)
Idiotype vaccination for patients with non-Hodgkin's lymphoma (1997) (0)
Idiotype vaccination for patients with B-cell lymphoma (1990) (0)
Abstract B055: Augmentation of OX40-dependent NK mediated antitumor activity is dependent on antibody cross-linking (2016) (0)
PET imaging of OX40+ activated T cells predicts therapeutic response in a murine cancer vaccine model (2018) (0)
Use of Dendritic Cells and GM-CSF Adjuvant Are Associated with Anti-Idiotype Cellular Immune Response Following Idiotype Vaccination in Follicular Lymphoma Patients. (2005) (0)
Antigen Selection in Human Lymphomagenesis1 (2006) (0)
antibodies : correlation with clinical responses Studies on B lymphoid tumors treated with monoclonal anti-idiotype (2005) (0)
Theraputic Antitumor Effect of Intratumoral Injection of RF-MCD40L in A B Cell Lymphoma Model (2006) (0)
A comparison of toxicity and stimulated immune responses from adjuvants used in idiotype vaccination of B cell lymphoma (1997) (0)
Abstract 3693: Single cell RNA-Seq of primary lymphomas reveals the diverse transcriptional states of the cancer immunologic milieu (2017) (0)
CD81: a novel lymphoma therapeutic target (2017) (0)
CpG in the Immunotherapy of B-Cell Lymphoma. (2005) (0)
Rapid Communication Diversity ofT-ceIl Antigen Receptor Variable GenesUsedbyMycosis Fungoides Cells (1992) (0)
vaccination for B-cell, non-Hodgkin's lymphoma Tumor-specific, cytotoxic T-lymphocyte response after idiotype (2011) (0)
First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular andOther CD20þNon-Hodgkin Lymphomas (2020) (0)
ANTI-CD20 ANTIBODY (MAB) IDEC-C2B8 IN RELAPSED LOW-GRADE/FOLLICULAR (LG/F) B-CELL NONHODGKIN??S LYMPHOMA (NHL). EXPANDED EFFICACY AND SAFETY RESULTS (1996) (0)
EFFECTIVE THERAPY BY ANTI‐CD81 AGAINST B CELL LYMPHOMAS ENGAGES BOTH DIRECT AND INDIRECT IMMUNE MECHANISMS (2017) (0)
CpG in the Immunotherapy of B Cell Lymphoma in an Animal Model (2004) (0)
Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B‐cell lymphoma receiving immunotherapy (2021) (0)
Specific cytotoxicity of drugs chemically linked to antibody. (1975) (0)
Gene-Specific Delineation of Copy Number Aberrations in Follicular Lymphoma with Molecular Inversion Probes. (2007) (0)
Abstract 251: Combining Ibrutinib with immune checkpoint blockade to induce therapeutic antitumor immune response in solid tumors (2015) (0)
Abstract 551: In situ vaccination with TLR9 agonist and anti-Ox40 antibody is sufficient to induce abscopal responses even in mice with spontaneous oncogene-driven tumors (2016) (0)
TLR-9 Activated Lymphoma B Cells Induce Anti-Tumor Immunity in a Murine Model (2008) (0)
Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation (2021) (0)
Short Title: Survival in Follicular Lymphoma (2017) (0)
Local Treg Immunomodulation Cures Metastatic Lymphoma Including CNS Sites (2011) (0)
Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN (2015) (0)
Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy (2012) (0)
T-regulatory cells and cures large lymphoma tumors Immunotransplantation preferentially expands T-effector cells over (2008) (0)
Single Cell RNA Sequencing of Serial Tumor and Blood Biopsies from Lymphoma Patients on an in Situ Vaccination Clinical Trial (2018) (0)
VaccineImmunogenicity of a Pulsed Dendritic Cell Self-Tumor Antigen Enhances the Linkage of Foreign Carrier Protein to a (2000) (0)
Rapid, Sustained B Cell Receptor Signaling in Lymphoma B Cells Differs from Normal Signaling in Tumor Infiltrating Nonmalignant B Cells. (2005) (0)
Correlation of IFNγ, CD107 and CD137 at the Single Cell Level Can Be Used To Monitor T Cell Responses in Patients after Immunotherapy. (2007) (0)
IDEC-C2B8-induced B cell depletion is not associated with significant immune suppression or infection (1997) (0)
Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking (2018) (0)
The Long Term Clinical Outcome of B Cell Lymphoma Patients Treated with Anti-Idiotype Monoclonal Antibody Correlated with the Isotype of the Therapeutic Antibody. (2006) (0)
Original Article Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemi- ologic study in the pre-rituximab era (2011) (0)
CpG Combined with Chemotherapy in the Immunotherapy of Large Tumor. (2004) (0)
Anti-Tumor Effect of Direct Intratumor Injection of Recombinant Fowlpox Virus Encoding CD40 Ligand in B Cell Lymphoma Model. (2005) (0)
FcγR IIIa polymorphism and anti-idiotype humoral immune response predict clinical outcome in follicular lymphoma patients receiving idiotypic vaccination (2004) (0)
Conception d’agents therapeutiques et agents therapeutiques (2005) (0)
Abstract CT133: Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in patients with low-grade B-cell lymphoma (2019) (0)
Antibody therapy (SY5-2) Chairpersons: Norihiro Nishimoto, Jeffrey V. Ravetch (2010) (0)
Therapeutic Antibodies Need To Interact With Fc Receptors (2017) (0)
Abstract 4045: Single cell RNA sequencing of serial tumor and blood biopsies from lymphoma patients undergoingin situvaccination (2019) (0)
DÃ©finitionof the High-Risk Acute Lymphoblastic Leukemia Patient by Immunological Phenotyping with Monoclonal Antibodies1 (2006) (0)
Abstract IA11: Monoclonal antibodies and in situ vaccination. (2015) (0)
Promotes Tumor Growth and Metastasis by Modulating the Functions of T Regulatory andMyeloid-Derived Suppressor Cells (2015) (0)
Efficient Transfer of CD40L mRNA into Mantle Cell Lymphoma for the Production of a Whole Tumor Cell Vaccine. (2007) (0)
Abstract 5568: Neoadjuvant immunotherapy for solid tumors (2020) (0)
Myelo- and lympho-proliferative disorders (WS-035) Chairpersons: Nagahiro Minato, Gilbert Faure (2010) (0)
A Subpopulation of Follicular Lymphoma Tumor Infiltrating T Cells Shows Suppressed Common Gamma Chain Cytokine Signaling. (2009) (0)
high-grade but not low-grade human lymphomas An epitope of the transferrin receptor is exposed on the cell surface of (2011) (0)
‘ ‘ focus on . . . ’ ’ session : transformation 086 SNP ARRAY GENOTYPING IN 182 DIAGNOSTIC FOLLICULAR LYMPHOMA CASES IDENTIFIES SITES OF AUPD ASSOCIATED WITH OVERALL SURVIVAL AND RISK OF TRANSFORMATION (2008) (0)
Dynamic Immune Modulation Seen By Single Cell RNA-Sequencing of Serial Lymphoma Biopsies in Patients Undergoing in Situ Vaccination (2019) (0)
Specificity Screening of Monoclonal Antibodies Obtained after Immunization with a Human Myeloma Cell Line (1983) (0)
Two I mmunoglobulin G F ragment C R eceptor P olymorphisms Independently P redict R esponse t o R ituximab i n P atients W ith Follicular L ymphoma (2003) (0)
Hybridoma monoclonal antibodies in the analysis fo human cell surface antigens (1981) (0)
Clinical Translation of a Prognostic Follicular Lymphoma Signaling Profile (2010) (0)
CVP alternating with fludarabine (CVP/F) chemotherapy prior to idiotype vaccination for follicular lymphoma (FL) (2007) (0)
monoclonal antibody Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 (2011) (0)
Abstract 2209: Costimulation of T cells by CD81 enhances CAR transduction of naive T cells (2016) (0)
A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma (2019) (0)
non-Hodgkin lymphoma does not predict clinical outcome after rituximab treatment in follicular Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells (2013) (0)
Abstract 648: Semi-synthetic peptibodies are a novel personalized therapeutic with activity against lymphomain vitroandin vivo (2014) (0)
Adoptive Therapy for Lymphoma with CD4 Memory T Cells Depleted of CD137-Expressing Tregs. (2009) (0)
Immunomodulation of NK Cells through 4-1BB (CD137) to Improve the Anti-Lymphoma Activity of Rituximab: Antibody-Based Anti-Lymphoma Synergy (2010) (0)
Pivotal Phase 2 Trial of Kte-C19 (anti-CD19 CAR T Cells) in Patients with Refractory Aggressive NHL (ZUMA-1) (2017) (0)
Abstract CT047: SD-101, a novel intratumoral class C CpG-ODN, given with low-dose radiation in patients with untreated low-grade B-cell lymphoma: interim results of a phase I trial (2016) (0)
T Regulatory Cells Exhibit Surface Expression of FoxP3 Derived Peptides Presented within Class I MHC (2015) (0)
Lymphoma: A Primary Role for Antibodies TCR Vaccines against a Murine T Cell (2003) (0)
793 RAG1 and 2 expression in the genesis of HIV associated non-Hodgkin's lymphomas (NHL) (1995) (0)
GenesThe Inference of Antigen Selection on Ig (2000) (0)
Methods for T cell activation in vivo by antigen pulsed dendritic cells (1995) (0)
Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma (2021) (0)
768 Systemic delivery of a tumor-targeted TLR9 agonist conjugate transforms the tumor immune landscape and induces tumor regression in mice (2021) (0)
Abstract 2440: CD47 is a prognostic factor and an antibody target that synergizes with rituximab to eradicate non-Hodgkin lymphoma (2010) (0)
Murine B Cell Lymphoma: Mechanism of DNA Vaccination Against the Idiotype of a (1999) (0)
Strategy to Obtain Monoclonal Anti-Idiotype Antibodies (1983) (0)
Abstract LB-238: Immunotransplant filters out regulatory T cells and cures large lymphoma tumors. (2008) (0)
in the Host or in the Tumor Itself Either Oligodeoxynucleotides Requires TLR9 Lymphoma Immunotherapy with CpG (2007) (0)
1166 Profiling the effects of targeted TLR9 stimulation within spontaneously arising breast tumors (2022) (0)
Abstract B061: CD81: A new target for therapy of B cell lymphoma (2016) (0)
XIII. The role of immunotherapy in the treatment of lymphoma (2011) (0)
Neoadjuvant Immunotherapy for Solid Tumors (2020) (0)
In Situ Vaccination Induces Changes in Follicular Lymphoma Tumor Cells That Correlate with Abscopal Clinical Regressions (2021) (0)
New drugs 346 POSITIVE CORRELATION BETWEEN CIRCULATING NK CELLS AND DISEASE RESPONSE IN MANTLE CELL LYMPHOMA (MCL) TREATED WITH LENALIDOMIDE: FIRST IN VIVO DATA SUPPORTING NK-MEDIATED CYTOTOXICITY AS A MECHANISM OF ACTION (2011) (0)
Generating Chimeric Antigen Receptors Utilizing Novel Anti-CD3 Nanobeads (2014) (0)
A CpG-Activated Whole-Cell Vaccine ‘Boost’ Enhances the Anti- Lymphoma Efficacy of Immunotransplant (2008) (0)
Abstract LB-139: In situ Treg immunomodulation at a single tumor site with CpG and immune checkpoint antibodies cures metastatic disease (2012) (0)
Rituximab A nti-CD20 M onoclonal A ntibody T herapy i n Non-Hodgkin's L ymphoma: S afety a nd E fficacy o f Re-Treatment (2000) (0)
Real-time pcr assay for quantitation of BCL-6 mRNA (2000) (0)
Novel Anti-CD19/Idiotype Bispecific Diabody Vaccine for B-Cell Lymphoma. (2009) (0)
Cytokine fusion constructs as DNA vaccines against tumors. (2000) (0)
A subset of lymphomas possess self-reactive BCRs (2012) (0)
The Percentage of Tumor-Infiltrating T Cells Is Not Correlated with Overall Survival in Follicular B-Cell Lymphomas. (2004) (0)
Abstract 3031: Positron emission tomography imaging of activated T cells by targeting OX40 reveals spatiotemporal immune dynamics and predicts response to in situ tumor vaccination (2018) (0)
RNA-Binding Protein VICKZ Is Expressed in a Germinal Center Associated Pattern among Lymphoma Subtypes. (2005) (0)
Therapeutic vaccination for lymphoid malignancy (2006) (0)
High Dose Radiolabeled Antibody Therapy of Lymphoma 1 (2006) (0)
Multiple HLA-DR antigens : Detection with monoclonal antibodies and translation . inovitro ( 13 chain-reactive antibody / Xenops oocytes / immunoprecipitation / one-and two-dimensional electrophoresis ) (2003) (0)
influences survival in follicular lymphoma patients A pluripotency signature predicts histologic tra (2012) (0)
LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study (2008) (0)
Antibody, Defines a New Family ofTransmembrane Proteins (1990) (0)
Combined Treatment with Short Synthetic Anti-Lymphoma Peptide and CpG ODN; A Therapeutic Vaccine Which cures the A20 Lymphoma in Balb/C Mice. (2008) (0)
Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP). (2016) (0)
Altered Peripheral Immune Phenotypes in Mantle Cell Lymphoma Survivors (2017) (0)
Treating B Cell Lymphomas with Anti CD81 Antibodies (2016) (0)
The Oncoprotein LMO2 Is Expressed in a Germinal Center B-Cell-Associated Pattern and Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma. (2006) (0)
HENRY KAPLAN MEMORIAL LECTURE: “IMMUNOTHERAPY COMES OF AGE TO TREAT LYMPHOMAS” (2017) (0)
Neither CD68+ Nor CD163+ Macrophages Are Associated with Decreased Survival in Follicular Lymphoma (2008) (0)
Preferential Proliferation of T Effectors and Tumor Protection by Adoptive Transfer of Primed Anti-Lymphoma Splenocytes into Lymphodepleted Hosts. (2007) (0)
Determinants of the Antitumor Effect of Kad iolabeIed Monoclonal Antibodies 1 (2006) (0)
Adaptive nanopore sequencing for single cell characterization of cancer mutations and gene rearrangements (2022) (0)
Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma (2022) (0)
Prevalence of Acquired N-Glycosylation Sites at the Single Cell Level in Follicular Lymphoma (2022) (0)
Lysine-Derived Charge-Altering Releasable Transporters: Targeted Delivery of mRNA and siRNA to the Lungs. (2023) (0)
Human red cells receptors and immune adherence haemagglutination (1972) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ronald Levy?

Ronald Levy is affiliated with the following schools: